Boehringer Ingelheim Group of companies
In 2011, Boehringer Ingelheim's sales increased by 5 %.
Financial Highlights
| Boehringer Ingelheim group of companies
|
2011
|
2010
|
Change
|
|---|---|---|---|
| Net sales
|
13,171 | 12,586
|
5 %
|
| Net sales by region
|
|||
| Europe
|
31 % | 32 %
|
|
| Americas
|
46 % | 46 %
|
|
| Asia, Australasia, Africa
|
23 % | 22 %
|
|
|
Net sales by business area |
|||
| Human Pharmaceuticals
|
93 % | 93 %
|
|
| Animal Health
|
7 % | 7 %
|
|
| Research and Development
|
2,516 | 2,453
|
3 %
|
| Personnel costs
|
3,664 | 3,358 | 9 %
|
| Average number of employees
|
44,094 | 42,224
|
4 %
|
| Operating income
|
2,272 |
1,896
|
20 %
|
| As % of net sales
|
17, 3 % | 15.1% | |
| Income after taxes
|
1,476 | 888
|
66 %
|
| As % of net sales
|
11,2 % | 7.1 %
|
|
| Shareholders' equity
|
7,466 |
6,474
|
15 %
|
| Return on shareholders' equity
|
22,8 % | 15.0 %
|
|
| Cash Flow
|
2,378 | 2,234
|
6 %
|
| Investments in tangible assets
|
458 | 519
|
-12 %
|
| Depreciation of tangible assets
|
535 | 498
|
7 % |
Amounts in millions of EUR, unless otherwise indicated
